
## Ashish V Chintakuntlawar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3787863/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
2	Evidence of Molecular Evolution Driven by Recombination Events Influencing Tropism in a Novel Human Adenovirus that Causes Epidemic Keratoconjunctivitis. PLoS ONE, 2009, 4, e5635.	1.1	201
3	Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma. Journal of Clinical Oncology, 2019, 37, 1909-1918.	0.8	150
4	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1943-1950.	1.8	86
5	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4506-4514.	1.8	86
6	Chemokine CXCL1/KC and its Receptor CXCR2 Are Responsible for Neutrophil Chemotaxis in Adenoviral Keratitis. Journal of Interferon and Cytokine Research, 2009, 29, 657-666.	0.5	75
7	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2012534.	2.8	72
8	Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 269-284.	1.2	58
9	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid, 2019, 29, 1615-1622.	2.4	51
10	Viral Capsid Is a Pathogen-Associated Molecular Pattern in Adenovirus Keratitis. PLoS Pathogens, 2010, 6, e1000841.	2.1	49
11	Adenovirus Type 37 Keratitis in the C57BL/6J Mouse. , 2007, 48, 781.		42
12	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	0.9	41
13	Caveolin-1 Associated Adenovirus Entry into Human Corneal Cells. PLoS ONE, 2013, 8, e77462.	1.1	40
14	First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study. Frontiers in Oncology, 2019, 9, 701.	1.3	38
15	Characterization of the oropharynx: anatomy, histology, immunology, squamous cell carcinoma and surgical resection. Histopathology, 2017, 70, 1021-1029.	1.6	36
16	Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers of the Head & Neck, 2016, 1, 11.	6.2	34
17	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
18	Esthesioneuroblastoma with distant metastases: Systematic review & metaâ€analysis. Head and Neck, 2018, 40, 2295-2303.	0.9	28

ASHISH V CHINTAKUNTLAWAR

#	Article	IF	CITATIONS
19	Cellular and Tissue Architecture of Conjunctival Membranes in Epidemic Keratoconjunctivitis. Ocular Immunology and Inflammation, 2010, 18, 341-345.	1.0	27
20	The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology. Hormones and Cancer, 2016, 7, 272-278.	4.9	22
21	Optimizing Lenvatinib Therapy in Patients with Metastatic Radioactive Iodine-resistant Differentiated Thyroid Cancers. Endocrine Practice, 2017, 23, 1254-1261.	1.1	22
22	Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. Head and Neck, 2019, 41, 1335-1341.	0.9	22
23	High-grade transformation of acinic cell carcinoma: an inadequately treated entity?. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 542-549.e1.	0.2	20
24	Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. , 2021, 9, e003019.		20
25	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid, 2020, 30, 1254-1262.	2.4	19
26	Human papillomavirus oropharynx carcinoma: Aggressive deâ€escalation of adjuvant therapy. Head and Neck, 2021, 43, 229-237.	0.9	19
27	Role of MyD88 in adenovirus keratitis. Immunology and Cell Biology, 2017, 95, 108-116.	1.0	18
28	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. Journal of the Endocrine Society, 2020, 4, bvaa069.	0.1	14
29	Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation. Oral Oncology, 2017, 72, 104-109.	0.8	12
30	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2346-e2357.	1.8	11
31	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	1.3	11
32	Thymoma-associated pancytopenia: immunosuppressive therapy is the cornerstone for durable hematological remission. Annals of Hematology, 2015, 94, 453-458.	0.8	9
33	Toxoplasmosis in patients with hematologic malignancies. Leukemia and Lymphoma, 2015, 56, 536-538.	0.6	9
34	T cell fraction impacts oncologic outcomes in human papillomavirus associated oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 111, 104894.	0.8	8
35	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Thyroid, 2021, 31, 332-333.	2.4	8
36	Molecular-Driven Therapy in Advanced Thyroid Cancer. Current Treatment Options in Oncology, 2021, 22, 24.	1.3	8

#	Article	IF	CITATIONS
37	Clinical and Molecular Profile Of Hereditary Antithrombin (AT) Deficiency: A Single Institution Cohort. Blood, 2013, 122, 2369-2369.	0.6	8
38	Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. International Journal of Endocrine Oncology, 2016, 3, 285-289.	0.4	7
39	Longâ€ŧerm oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients. International Forum of Allergy and Rhinology, 2022, 12, 1457-1467.	1.5	7
40	Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, e131-e137.	0.4	6
41	Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. Journal of the Endocrine Society, 2022, 6, bvac044.	0.1	5
42	Survival outcomes in locally advanced cutaneous squamous cell carcinoma presenting with clinical perineural invasion alone. Head and Neck, 2021, 43, 1995-2001.	0.9	4
43	Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus–Associated Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2021, 165, 830-837.	1.1	4
44	Immuneâ€related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	2.0	4
45	Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer. Oral Oncology, 2021, 123, 105625.	0.8	4
46	Drug–drug interaction between bosutinib and warfarin. Leukemia and Lymphoma, 2014, 55, 2213-2214.	0.6	3
47	Human Papillomavirus–Associated Anogenital Pathology in Females With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2021, 164, 369-374.	1.1	2
48	Second Primary Tumors in Patients Presenting With Unilateral HPV â€Associated Tonsillar Squamous Cell Carcinoma. Laryngoscope, 2021, , .	1.1	2
49	Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy. Practical Radiation Oncology, 2022, 12, 113-119.	1.1	2
50	A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies Journal of Clinical Oncology, 2022, 40, TPS6111-TPS6111.	0.8	1
51	Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. Journal of Oncology Practice, 2016, 12, 521-522.	2.5	Ο
52	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	1.5	0
53	Reply to A.S. Garden. Journal of Clinical Oncology, 2019, 37, 3559-3560.	0.8	0
54	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma. , 2021, , 246-254.e3.		0

#	Article	IF	CITATIONS
55	Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx. International Journal of Radiation Oncology Biology Physics, 2021, 110, 396-402.	0.4	0
56	Metastatic Esthesioneuroblastoma: A Systematic Review and Meta-analysis. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.4	0
57	Induction Chemotherapy before Surgical Resection for Patients Presenting with Unresectable Esthesioneuroblastoma. , 2019, 80, .		Ο
58	Anaplastic Thyroid Cancer: Surgery orÂNot in Locally Advanced Disease. , 2021, , 383-390.		0
59	Emerging Disparities in Prevention and Survival Outcomes for Patients with Head and Neck Cancer and Recommendations for Health Equity. Current Oncology Reports, 2022, , 1.	1.8	0